This is the first demonstration that an antiviral drug can prevent a viral sexually transmitted disease, said Corey, also a professor of laboratory medicine at UW and head of Fred Hutchinson’s infectious diseases program. Almost 80 percent of persons with HSV-2 are not diagnosed because accurate blood tests to detect antibodies signifying infection with the virus have only recently been developed and are not widely used. At the end of the eight-month study period, genital herpes had occurred in 27 of the sexual partners of those on placebo versus 14 who took valacyclovir, as judged by the antibody-blood test. Antiviral Drug, Valacyclovir, Reduces Genital Herpes Transmission. Date: January 1, 2004 Source: Fred Hutchinson Cancer Research Center Summary: An international team of researchers finds that taking a single daily dose of an approved antiviral drug known as valacyclovir can reduce the transmission of genital herpes to uninfected partners by 50 percent. Larry Corey, a member of Fred Hutchinson Cancer Research, conducted a study of nearly 1,500 heterosexual monogamous couples in which one partner had genital herpes and the other did not. Almost 80 percent of persons with HSV-2 are not diagnosed because accurate blood tests to detect antibodies signifying infection with the virus have only recently been developed and are not widely used. Antiviral Drug Sharply Reduces Return of Herpes of the Eye. This infection can produce a painful sore on the eyelid or surface of the eye and cause inflammation of the cornea, the transparent tissue that covers the front of the eye. The study clearly shows that acyclovir therapy can benefit people with all forms of ocular herpes, said Dr.
The efficacy of Valtrex for the reduction of transmission of genital herpes in individuals with multiple partners and non heterosexual couples has not been established. Based on efficacy data from clinical trials with oral acyclovir, treatment with Valtrex should be initiated within 24 hours after the onset of rash see Clinical Studies (14. The efficacy of valacyclovir and acyclovir on genital herpes simplex virus (HSV) shedding was assessed in a double-blind, 3-period crossover trial. Standard serologic testing for HIV was done. The significance of suppressing HSV shedding with antiviral medication was recently demonstrated in a large international, randomized, placebo-controlled trial 24. Disease symptoms often interfere with every-day activities and occasionally these infections are the cause of life-threatening or sight-impairing disease, especially in neonates and the immuno-compromised patient population. In a test tube study, astragalus was found to have anti herpes simplex virus activity. Pharmaceutical genital herpes treatment, using medication The CDC has established that three oral antiviral drugs are recommended for the treatment of genital herpes infection: acyclovir, valacyclovir, and famciclovir medications. Statistics A national survey of the US population conducted between 1988 and 1994 found that more than one in five people over 12 had blood tests that showed evidence for infection with herpes simplex virus 2 (HSV 2), the virus typically responsible for genital herpes.
The study of 1,484 couples conducted in support of the application showed that once-daily suppressive therapy with VALTREX, in addition to counseling on safer sex practices, reduced the risk of transmission of symptomatic genital herpes (signs or symptoms of GH) by 75 percent and reduced the risk of overall acquisition of the virus by 48 percent. While genital herpes is not a life-threatening disease, once infected, the virus never leaves the body, making it a lifelong condition that can recur at various times with or without symptoms. People with genital herpes can still infect their sex partners — even if they are taking anti-herpes drugs that prevent herpes outbreaks. This led Johnston’s team to conduct three intensive new studies. GlaxoSmithKline conducted a study testing the genital herpes transmission rate of people using the anti-viral drug Valtrex and placebos. The follow are the results of the study:.
Genital herpes (GH) recurrences and viral shedding are more frequent in the first year after initial HSV-2 infection. Our study is the first to demonstrate a significant reduction in viral shedding with valacyclovir 1 g daily compared to placebo in a population of subjects newly diagnosed with HSV-2 infection. More recent studies have shown that suppressive antiviral therapy is as effective at controlling symptomatic disease in recently infected persons as it is in those with prevalent infection 18, 19. GSK conducted an 8 month international study for this approval and the study showed that using 500 mg of Valtrex once daily resulted in a 75 reduction in transmission of symptomatic genital herpes infection, and also showed a 48 reduction in the acquisition asymptomatic acquisition of herpes-2 documented by HSV-2 seroconversion during the study. GSK conducted an 8 month international study for this approval and the study showed that using 500 mg of Valtrex once daily resulted in a 75 reduction in transmission of symptomatic genital herpes infection, and also showed a 48 reduction in the acquisition asymptomatic acquisition of herpes-2 documented by HSV-2 seroconversion during the study. Viral shedding was also reduced by persons taking Valtrex 500 mg once daily in the study. It is known that partners infected with genital herpes can transmit the infection to an uninfected partner BOTH when symptoms are present (such as redness and blisters) as well as when no symptoms are present (called asymptomatic shedding; see the paper on Asymptomatic Shedding at www. This profound reduction of viral particles was so significant that it made sense to do a research study to see if, indeed, that fewer uninfected partners became infected when the infected partner took antiviral medication regularly. With half of the couples the infected partner took Valtrex, and in the other half the infected partner took placebo. Nucleoside analogues against herpes simplex virus (HSV) have been shown to suppress shedding of HSV type 2 (HSV-2) on genital mucosal surfaces and may prevent sexual transmission of HSV. The partners with HSV-2 infection were randomly assigned to receive either 500 mg of valacyclovir once daily or placebo for eight months. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. Use of the antiviral decreased transmission rates even when compared to occasional condom use in the placebo group. Researchers conducting this study tested resveratrol as a topical cream to treat mice infected with HSV. The greater antiviral activity of acyclovir against HSV compared to VZV is due to its more efficient phosphorylation by the viral TK. Sensitivity testing results, expressed as the concentration of drug required to inhibit by 50 the growth of virus in cell culture (IC 50 ), vary greatly depending upon a number of factors. Recurrent Episodes: Three double-blind trials (2 of them placebo-controlled) in immunocompetent adults with recurrent genital herpes were conducted. Recurrence Rates in HIV-Infected Adults at 6 Months. Reduction of Transmission of Genital Herpes: A double-blind, placebo-controlled study to assess transmission of genital herpes was conducted in 1,484 monogamous, heterosexual, immunocompetent adult couples.
Fda Approves Valtrex(r) Caplets For Reducing Risk Of Spreading Genital Herpes
The analysis led to the conclusion that all three antiviral therapies were highly effective compared with a placebo and reduced the global relative risk of recurrence by nearly 50 percent. In the case of valacyclovir, this particular study, conducted by some of the most noted HSV researchers in the field, demonstrated that daily therapy with valacyclovir could cut the risk of transmission to an uninfected partner in half. The study followed 1,484 heterosexual couples in which one partner was seropositive for genital HSV2 and had a history of recurrences, while the other was uninfected with genital herpes. Optimal management of genital herpes includes accurate diagnosis, antiviral therapy, and counseling of patients about complications and transmission of herpes simplex virus (HSV). Time to first clinical Hazards rate for VAL vs. Genital and labial herpes simplex virus infections are frequently encountered by primary care physicians in the United States. Acyclovir, valacyclovir hydrochloride, and famciclovir are the 3 antiviral drugs routinely used to treat symptomatic herpes simplex virus (HSV) infections. A 2003 study of prophylactic valacyclovir was conducted at a month-long wrestling camp. In a study of nearly 10,000 babies born at or near full term in Britain in the same week in 1958, those who weighed less than about 5. Antiviral drug may reduce spread of genital herpes. In an eight-month study of more than 1,400 people with genital herpes, valacylovir hydrochloride (Valtrex) reduced transmission to partners by up to 77 in those who took the drug compared with those who took a placebo.